Drug Profile
Emfilermin
Alternative Names: AM 424; Leukaemia inhibitory factor; Leukemia inhibitory factor; LIF; recombinant leukaemia inhibitory factor; Recombinant leukaemia inhibitory factor protein - Ares-Serono; Recombinant LIF protein - Ares-Serono; rhLIFLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Walter and Eliza Hall Institute of Medical Research
- Class Cytokines; Neuroprotectants
- Mechanism of Action Leukaemia inhibitory factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Female infertility; Neuromuscular disorders
Most Recent Events
- 23 Jun 2004 Data from a media release have been added to the Women's Health therapeutic trials section
- 04 Jun 2004 Serono has completed the international proof-of-concept phase II trial with emfilermin for female infertility
- 07 Jul 2003 Data from a media release have been added to the adverse events and Women's health therapeutic trials sections